Scientists hunt for a yardstick to measure rare nerve damage
NCT ID NCT07651540
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This study aims to find the most useful clinical scale for tracking sensory neuronopathy, a rare condition that damages nerve cells and can cause severe disability. Researchers will follow 70 adults for 12 months, testing several rating scales at each visit. The goal is to identify a tool that reliably measures disease progression, which could improve patient monitoring and treatment evaluation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SENSORY NEURONOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU St Etienne
Saint-Etienne, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu D Angers
Angers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Clermont Ferrand
Clermont-Ferrand, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Grenoble
Grenoble, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de La Reunion
Saint-Pierre, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Lille
Lille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Limoges
Limoges, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Nancy
Nancy, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Nantes
Nantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Nice
Nice, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Saint-Etienne
Saint-Etienne, 42055, France
-
Chu de Toulouse
Toulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chuv Centre Hospitalier Vaudois
Lausanne, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital de Sion
Sion, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital, Bicetre
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopitaux Universitaire de Geneve
Geneva, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopitaux Universitaire de Marseille
Marseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopitaux Universitaire de Strasbourg
Strasbourg, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospices Civils de Lyon
Lyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could identify a reliable way to measure disease progression in sensory neuronopathy, helping doctors better track and manage the condition.
What could go wrong
This is an observational study, not a treatment trial. It may not find a clear winner among the scales, and results may not apply to all patients with sensory neuronopathy.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.